Home / Companies / Boehringer Ingelheim Pharmaceuticals Inc / Trends
Boehringer Ingelheim Pharmaceuticals Inc H-1B trends
Quarterly LCA aggregate trend points for Boehringer Ingelheim Pharmaceuticals Inc. Each point carries filing counts, distinct employers, distinct role titles, SOC coverage, wage metrics, certification counts, and source IDs when returned.
Summary
H-1B LCA filings for Boehringer Ingelheim Pharmaceuticals Inc span 2016 Q2 to 2026 Q2, peaking at 55 filings in 2021 Q3.
The most recent reported period (2026 Q2) shows 9 filings.
LCA filings are labor-condition applications certified by the U.S. Department of Labor, not active job postings or approved USCIS H-1B petitions.
| Period | LCA count | Role titles | SOC codes | Avg wage low | Avg prevailing | Certified | Certification rate |
|---|---|---|---|---|---|---|---|
| 2016 Q2 | 40 | 28 | 11 | $110,726 | $94,829 | 40 | 100.0% |
| 2017 Q2 | 31 | 26 | 14 | $117,444 | $102,455 | 29 | 93.5% |
| 2018 Q2 | 24 | 19 | 10 | $112,944 | $97,530 | 22 | 91.7% |
| 2019 Q2 | 54 | 35 | 14 | $111,924 | $96,025 | 54 | 100.0% |
| 2020 Q1 | 2 | 2 | 2 | $117,343 | $107,287 | 2 | 100.0% |
| 2020 Q2 | 37 | 27 | 11 | $126,015 | $100,113 | 36 | 97.3% |
| 2020 Q3 | 13 | 11 | 8 | $114,963 | $96,360 | 13 | 100.0% |
| 2020 Q4 | 6 | 6 | 3 | $105,397 | $84,566 | 6 | 100.0% |
| 2021 Q2 | 41 | 32 | 11 | $116,379 | $90,471 | 41 | 100.0% |
| 2021 Q3 | 55 | 39 | 12 | $114,349 | $90,590 | 55 | 100.0% |
| 2021 Q4 | 8 | 6 | 6 | $169,928 | $124,701 | 8 | 100.0% |
| 2022 Q1 | 7 | 6 | 6 | $140,564 | $120,699 | 6 | 85.7% |
| 2022 Q2 | 28 | 21 | 9 | $127,654 | $104,778 | 28 | 100.0% |
| 2022 Q3 | 17 | 14 | 8 | $126,380 | $108,085 | 17 | 100.0% |
| 2022 Q4 | 8 | 8 | 8 | $151,823 | $128,734 | 8 | 100.0% |
| 2023 Q1 | 3 | 3 | 3 | $139,622 | $122,373 | 3 | 100.0% |
| 2023 Q2 | 16 | 11 | 8 | $135,670 | $115,690 | 16 | 100.0% |
| 2023 Q3 | 16 | 12 | 7 | $139,835 | $122,139 | 16 | 100.0% |
| 2023 Q4 | 8 | 8 | 4 | $164,627 | $150,650 | 8 | 100.0% |
| 2024 Q1 | 4 | 4 | 4 | $128,658 | $105,378 | 4 | 100.0% |
| 2024 Q2 | 18 | 10 | 6 | $129,085 | $105,165 | 18 | 100.0% |
| 2024 Q3 | 19 | 14 | 5 | $154,191 | $126,237 | 19 | 100.0% |
| 2024 Q4 | 1 | 1 | 1 | $130,000 | $116,293 | 1 | 100.0% |
| 2025 Q1 | 4 | 4 | 4 | $146,736 | $129,098 | 4 | 100.0% |
| 2025 Q2 | 20 | 13 | 9 | $131,802 | $118,141 | 19 | 95.0% |
| 2025 Q3 | 12 | 12 | 8 | $209,263 | $168,326 | 12 | 100.0% |
| 2025 Q4 | 10 | 9 | 7 | $160,569 | $130,208 | 10 | 100.0% |
| 2026 Q2 | 9 | 6 | 3 | $164,002 | $131,304 | 9 | 100.0% |
Frequently asked questions
- How have H-1B filings for Boehringer Ingelheim Pharmaceuticals Inc changed over time?
- H-1B LCA filings for Boehringer Ingelheim Pharmaceuticals Inc span 2016 Q2 to 2026 Q2, peaking at 55 filings in 2021 Q3. The most recent reported period (2026 Q2) shows 9 filings. LCA filings are labor-condition applications certified by the U.S. Department of Labor, not active job postings or approved USCIS H-1B petitions.
Get this page with API
Rendered from the bluedoor H-1B Jobs API. Reproduce it:
GET https://api.bluedoor.sh/h1b-jobs/v1/trends?company=boehringer+ingelheim+pharmaceuticals+inc&metric=lca_countJSON